Bayesian Capital Management, LP Intellia Therapeutics, Inc. Transaction History
Bayesian Capital Management, LP
- $600 Million
- Q2 2025
A detailed history of Bayesian Capital Management, LP transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Bayesian Capital Management, LP holds 23,600 shares of NTLA stock, worth $289,572. This represents 0.04% of its overall portfolio holdings.
Number of Shares
23,600Holding current value
$289,572% of portfolio
0.04%Shares
8 transactions
Others Institutions Holding NTLA
# of Institutions
338Shares Held
96.9MCall Options Held
1.66MPut Options Held
1.03M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$160 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$133 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$118 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.12MShares$50.5 Million0.0% of portfolio
-
State Street Corp Boston, MA4.04MShares$49.6 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $933M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...